Latest Market Entry News

Australian Agricultural Company (ASX:AAC) defies North Queensland floods to deliver a 23% jump in operating profit, driven by strong beef pricing and herd valuation gains.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

BLIS Technologies posted a 16% revenue increase to $14.7 million in FY26, resolving a key intellectual property dispute and expanding strategic partnerships, including an extended Probi AB agreement that now covers pet nutrition.

Cleo Diagnostics has laid out a clear U.S. reimbursement pathway for its ovarian cancer test, leveraging an existing CPT code to enable early market entry and data collection ahead of FDA clearance.

Complii FinTech Solutions has landed a strategic two-year deal with a major financial institution, marking its entry into the institutional market segment and positioning the company for scalable growth in capital raising software services.

Smart Parking Limited grew its ANPR sites by 17% in Q3 FY26 and increased parking breach notices by 19%, leveraging acquisitions and AI technology to expand across Europe and New Zealand.

Nexsen has secured a strategic partnership with GHK Hospital Limited in Hong Kong, marking a significant step in validating and commercialising its rapid point-of-care diagnostics across North Asia.

Temple & Webster has delivered its most profitable April ever with EBITDA hitting around $2.5 million, setting the stage for a near doubling of earnings in FY27 despite weak consumer confidence.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

Avecho Biotechnology has bolstered its cash reserves by $1.9 million through the exercise of listed options, positioning the company for a pivotal Phase III interim analysis readout for its insomnia treatment.

4DS Memory is accelerating commercialisation of its 60nm ReRAM technology in India, aligning with the country’s AUD$25 billion semiconductor investment and targeting mature-node industrial and defence sectors.

Green360 Technologies has landed its first named commercial customer for Eco-Clay, signing a non-binding MOU with Holcim Australia to supply up to 4,800 tonnes over 12 months, marking a key step in commercialising its low-carbon cement replacement.